Welcome to PwC’s monthly issue of the Life Sciences Newsbrief. This publication provides you with a snapshot of developments in the Canadian and global life sciences industry along with upcoming Canadian events and thought leadership. If you need further information, please contact any of the life sciences professionals listed on the right.
Aspiring giants: How small pharmas can drive to $1 billion — and beyond
Only a few small companies have managed to catapult their revenue over the $1 billion mark over the past two decades in the global pharmaceutical industry. Whether they chose to expand their therapeutic area focus and product portfolios, enter new geographies, or grow their core business, these aspiring giants pursued three distinct strategies to jump-start growth. PwC's report studies 30 companies that catapulted themselves beyond the $1 billion revenue mark and identifies what smaller, ambitious pharmaceutical companies should do to earn their first $1 billion in annual revenues. Click here to download the report.
Money Tree Q3 2011 Life Sciences Report: Reaching for Growth
According to PwC's quarterly Money Tree Report, life sciences venture capital falls short of strong second-quarter performance, but year-over-year trend remains positive. Following two quarters of growth, Venture capital (VC) funding in the life sciences sector, which includes the biotechnology and medical device industries, fell 18 percent during the third quarter of 2011, according to a new PwC US report, "Reaching for Growth." The report includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree Report, based on data from Thomson Reuters. Click here to download the report.
Top health industry issues of 2012 — How the Payer, Provider and Pharma/Life Sciences sectors will be impacted in 2012
The annual Health Research Institute's (HRI) 'Top Issues' report focuses on economic, regulatory and political forces which are all putting pressure on the industry. For 2012, the key issues include: defining and paying for value; how higher out-of-pocket costs cramp utilization; providers and insurers teaming up for population health, and more. To read the full report, click here.
PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, the development of new prospects for early detection testing and a review of significant events for the development of personalized medicine. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies. Click here to read the report.
Personalized Medicine World Conference 2012
January 23 – 24, 2012, Silicon Valley, CA
PwC is a sponsor at the Personalized Medicine World Conference (PMWC), the only fully integrated conference to examine the advances and challenges of personalized medicine through a practical lens. PMWC features thought leaders of business, government, health care delivery, research and technology at the two-day conference.